Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Merck
Medtronic
McKesson
Dow

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Litigation Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)

See Plans and Pricing

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)

Docket   Start Trial Date Filed 2011-11-03
Court District Court, D. Delaware Date Terminated 2014-09-17
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To
Parties ACTAVIS INC.; ACTAVIS SOUTH ATLANTIC LLC; ACTAVIS, INC.; LTS LOHMANN THERAPIE-SYSTEME AG; NOVARTIS AG; NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD.; NOVARTIS PHARMA AG; NOVARTIS PHARMACEUTICALS CORPORATION; PAR PHARMACEUTICAL INC.; WATSON LABORATORIES INC.; WATSON PHARMA INC.; WATSON PHARMACEUTICALS INC.
Patents 6,316,023; 6,335,031; 6,699,498
Attorneys Andrea M. Houston; C. Nicole Gifford; Daniel G. Brown; Daniel M. Silver; Dominick T. Gattuso; Erika R. Caesar; Erin A. Thomson; Gina R. Gencarelli; Jaclyn C. Levy; James L. Higgins; Jennifer Koh; Katharine Crawford Lester; Melanie K. Sharp; Michael P. Kelly; Michelle R. Ma; Robert M. Vrana; Stephen M. Hash; Steven J. Fineman
Firms Ballard Spahr LLP; Friedlander & Gorris, P.A.; Proctor Heyman LLP; Richards, Layton & Finger, PA; Young, Conaway, Stargatt & Taylor LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc. (D. Del. 2011)

Date Filed Document No. Description Snippet Link To Document
2013-11-01 319 is not an oxidizing environment L`§.S poteet 6,699,498 (the “L'l`S petent’”‘), assigned to ]§*.§e…et limited States patents 6,3 35. l(“°OB] patent ) and 6 ,.3]6 {}23 (_ “’GZB patent ’) {_e~t)§leetivety…far below the threshold set by the LTS patent 'i`hc patents in colt also z‘ecognize that “co'l.npound…Composition” Ciaims {3 and 7 of the ’031 patent and 2 and 7 of the . ’{323 patent) I.~ ’}"here is No Evidenee…quot;’ C1aims (3 and 7 0'1" 1110 ’{)3 1 patent and 2 and 7 of the "023 paf‘enf) ........ External link to document
2014-06-18 40 detecting peroxides. U.S. Patent No. 6,699,498, 2:58- 62 ("the '498 patent") ("The peroxide…the '023 patent") (collectively, "the patents in suit"). Both patents share the same…that the patent examiner for the '023 and '031 patents considered both the '807 patent and U.S…alleging infringement of U.S. Patent Nos. 6,335,031 ("the '031 patent") and 6,316,023 ("…16, and 18 of the '031 patent and claims 2 and 7 of the '023 patent. Watson counters that the External link to document
2014-06-18 414 detecting peroxides. U.S. Patent No. 6,699,498, 2:58- 62 ("the '498 patent") ("The peroxide…the '023 patent") (collectively, "the patents in suit"). Both patents share the same…that the patent examiner for the '023 and '031 patents considered both the '807 patent and U.S…alleging infringement of U.S. Patent Nos. 6,335,031 ("the '031 patent") and 6,316,023 ("…16, and 18 of the '031 patent and claims 2 and 7 of the '023 patent. Watson counters that the External link to document
2014-08-29 426 infringement of U.S. Patents Nos. 6,335,031 ("the '031 patent") and 6,316,023 ("the '…#39;023 patent") (collectively, "the patents in suit"). Both patents share the same specification…Par's ANDA products infringe claim 7 of the '031 patent. Par should submit an agreed upon form of final…). 3 Novartis listed the '031 and '023 patents in the Food and Drug Administration's "…citations to the specification refer to the '031 patent. 3 Unless otherwise noted, all citations to the External link to document
2014-09-17 429 not infringe U.S. Patent No. 6,316,023 ("the '023 patent"); and it is further …any valid claim of U.S. Patent No. 6,335,031 ("the '031 patent"); and whether those… 16 and 18 of the '031 patent and claims 2 and 7 of the '023 patent are not obvious; … No. 202339, do not infringe the '031 patent; and it is further ORDERED AND …ANDA No. 202339, does not infringe the '031 patent; and it is further ORDERED AND External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Harvard Business School
AstraZeneca
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.